Theranos in Criminal Probe

Federal officials are investigating whether the diagnostics company misled investors.

Written byKerry Grens
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Theranos CEO Elizabeth HolmesWIKIMEDIA, MAX MORSE FOR TECHCRUNCHBlood-testing company Theranos continues its downward spiral, from a promising biotech with intriguing—yet mysterious—innovations to a company under investigation for criminal activity. In an April 18 company memo distributed by Business Insider, Theranos disclosed that the Securities and Exchange Commission (SEC) and the US Attorney’s Office were conducting investigations into the firm.

As The Wall Street Journal reported, prosecutors are “examining whether Theranos misled government officials, which can be a crime under federal law,” while the SEC is “examining whether Theranos made deceptive statements to investors when it solicited funding.”

The company, which offers finger-prick, blood-based tests for certain medical conditions, was already in trouble with the Centers for Medicare and Medicaid Services over concerns of substandard laboratory conditions. And skepticism has been mounting over just how well Theranos’s tests work.

CEO Elizabeth Holmes yesterday (April 18) told NBC’s Today that her company had stopped testing and has “taken the approach of saying, ‘Let’s rebuild this entire laboratory from scratch. So that we can ensure it never happens again.’”

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies